2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Molecular Testing, Omics Technologies, Pathology, Bioinformatics, Clinical Procedures, Computational Biology, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Therapy Sequence, Biological Therapies, Transplantation, Monoclonal Antibody Therapy, Adverse Events, Artificial Intelligence (AI), Machine Learning, Biological Processes, Pathogenesis, CHIP, Genomics, Hematopoiesis, Immune Mechanism, Molecular Biology, Clinical Practice (Health Services and Quality), Patient Safety, Practice Models, Quality of Care, Diseases, Hemoglobinopathies, Sickle Cell Disease, Thalassemia, Immunology, GVHD, Lymphoid Malignancies, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Research, AML, Translational Research, MDS, Clinical Research, Clinical Trials, Health Outcomes Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Study Population, Human, Adult, Elderly, Pediatric, Animal Model
PAPER

2482 Day 30 T-cell states differ by graft source after hematopoietic stem cell transplantation for pediatric acute myeloid leukemia

Alba Sommerschield, MD, Anthony Anselmo, PhD2, Aaron Thorner, dfci3, Chiara Wychera, MD4, Francesca Alvarez Calderon, MD, PhD5, Leslie Kean, MD, PhD6, Susan Prockop, MD7, Jared Rowe, MD, PhD8, Ulrike Gerdemann, MD9, Franziska Wachter, MD10
1 Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, Harvard Medical School, Boston, United States
2 Center for Cancer Genomics, Dana-Farber Cancer Institute, Boston, United States
3 Center for Cancer Genomics, Dana-Farber Cancer Institute, Boston, United States
4 Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, Harvard Medical School, Boston, United States
5 Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, Harvard Medical School, Boston, United States
6 Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, Harvard Medical School, Boston, United States
7 Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, Harvard Medical School, Boston, United States
8 Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, Harvard Medical School, Boston, United States
9 Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, Harvard Medical School, Boston, United States
10 Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, Harvard Medical School, Boston, United States

Early immune reconstitution after hematopoietic stem cell transplantation (HCT) influences infection control, graft-versus-leukemia activity, graft-versus-host disease, and relapse. Prior studies have examined CD4-biased recovery after cord blood (CBU) transplantation (Hiwarkar P, 2017), T-cell receptor (TCR) repertoire evolution (Gkazi AS, 2018), differences in CBU and bone marrow (BM) graft composition, and post-transplant marrow T-cell states (Wang J, 2023). However, how graft source jointly shapes transcriptional T-cell states and clonal dynamics in the early recipient marrow remains unclear. Moving beyond the previously reported phenotypic graft composition differences  we  used paired single-cell RNA/TCR sequencing to compare early T-cell reconstitution after CBU versus BM transplantation in pediatric AML.

Methods: Paired single-cell RNA and TCR sequencing was performed on bone marrow collected ~30 days after HCT. The primary cohort comprised pediatric AML patients in MRD-negative remission receiving BM (n=3) or CBU (n=5) grafts. From 105,825 cells, 15,869 T-cells were merged, clustered, and annotated using canonical lineage markers and the Novershtern dataset reference (Novershtern N, 2011). Cluster composition was evaluated by CD4/CD8 lineage, graft source, and patient origin. Differential expression was computed separately for CD4 and CD8 T-cells using a pseudobulk approach, followed by gene set enrichment analysis. Paired TCR data were used to distinguish polyclonal reconstitution from dominant-clonotype expansion within patient-associated clusters. Sample collection was IRB-approved.

Results: Graft source profoundly shaped T-cell abundance and transcriptional identity, despite recovery of all major T-cell populations in both BM and CBU recipients. Recovery was CD8-skewed in BM recipients (CD4:CD8 0.4–0.8), and CD4-skewed in CBU recipients (CD4:CD8 1.6–7). We analyzed the graft-source–specific transcriptional signatures that define T-cell state clusters in recipients of CBU and BM HCT: CBU enriched clusters identified resting naïve-like and IL7R? helper CD4 cells, FOXP3? regulatory T-cells, GZMK? activated-memory CD4 cells, and, uniquely, cycling S/G2M and proliferative cytotoxic populations indicative of active homeostatic proliferation, along with a previously unreported graft-source-specific TRDV1?ZNF683? Vδ1-like compartment. In contrast, BM clusters displayed mature FGFBP2?CX3CR1?GZMB? cytotoxic CD8 cells and TRDV2?TRGV9? Vγ9Vδ2 T-cells, indicating that the two grafts seed structurally distinct effector and unconventional T-cell landscapes in the reconstituting marrow.

Gene set enrichment analysis of differentially expressed genes showed that T cells from CBU recipients, particularly CD8 T cells, were enriched for TNFα-NFκB, inflammatory response, complement, IL6-JAK-STAT3, and IL2-STAT5 signaling. The expression of activation- and stress-associated genes (NR4A1/2/3, FOS, JUN, TNFAIP3, NFKBIA, CD69, TNF, IL15, IL18, HIF1A, SOCS3, and CD70) supported an activated, cytokine-responsive, and stress-adapted T-cell state. This coordinated induction of immediate-early, NF-κB, and cytokine-STAT programs is consistent with T-cells undergoing lymphopenia-driven homeostatic expansion in a cytokine-rich environment, rather than antigen-experienced terminal differentiation. In contrast, BM-derived recipient CD8 T-cells displayed terminal-effector and cytotoxic programs, consistent with the transfer and persistence of pre-formed memory/effector clones from the BM graft.

Unexpectedly, these pronounced transcriptional differences arose without any accompanying difference in TCR repertoire diversity: Simpson clonality and Shannon diversity indices were comparable between CBU and BM recipients, indicating similar overall repertoire breadth and evenness despite the divergent cell states.

Conclusions: At day 30 after HCT for pediatric AML, graft source strongly shaped marrow T-cell composition and state. BM recipients showed mature cytotoxic CD8 programs, whereas CBU recipients demonstrated CD4-skewed recovery, broader helper and regulatory states, active proliferation, and cytokine-responsive CD8 programs. Despite these marked transcriptional differences, TCR diversity was similar between groups. To our knowledge, this is the first paired single-cell RNA/TCR comparison of early recipient-marrow T-cells after BM versus CBU transplantation, suggesting that graft source primarily shapes T-cell state rather than clonal diversity.

Franziska Wachter, MD: No relevant conflicts of interest to declare.